Valganciclovir

Breastfeeding
  • TRADE NAME: Valcyte (Roche)
  • INDICATIONS: Cytomegalovirus retinitis (CMV) in patients with AIDS, prevention of CMV disease in high-risk transplant patients
  • CLASS: Antiviral, Guanine nucleoside analog
  • HALF-LIFE: 4 hours (in severe renal impairment up to 68%)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Abacavir, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Emtricitabine, Tenofovir Disoproxil

PREGNANCY CATEGORY: N/A
May cause fetal toxicity based on findings in animal studies

Valganciclovir is rapidly converted to ganciclovir in the body.

HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS

See full prescribing information for complete boxed warning.

Our database has 19 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CENTRAL NERVOUS SYSTEM
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
OCULAR
OTHER


Page last updated 07/27/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top